MedTrace Logo

Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer

NCT03367871 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2024-06-18

Study results available
· View outcomes & findings →

Summary

The investigators propose to evaluate the efficacy of the combination of standard chemotherapy with bevacizumab with Pembrolizumab in women with recurrent, persistent, or metastatic cervical cancer.

Conditions

Interventions

DRUG

Pembrolizumab

IV

DRUG

Paclitaxel

Administered intravenously (IV) on day 1

DRUG

Cisplatin

Administered intravenously (IV) on day 1

DRUG

Carboplatin

Administered intravenously (IV) on day 1

DRUG

Bevacizumab

Administered intravenously (IV) on day 1

Sponsors & Collaborators

Principal Investigators

  • Marilyn Huang, MD, MS · University of Miami

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-06
Primary Completion
2023-01-30
Completion
2023-01-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03367871 on ClinicalTrials.gov